Otsuka Holdings: Report on the status of share buybacks (based on Article 24-6, Paragraph 1 of the law).
Otsuka Holdings: Notice regarding treasury stock acquisition results, end of acquisition, and number of cancelled shares
Otsuka Holdings: Notification of Completion of Share Repurchase and Number of Treasury Stock to be Cancelled
Otsuka Holdings: Interim report
Otsuka Holdings: Correction Issuance Registration Form
Otsuka Holdings: Otsuka Pharmaceutical Plant establishes a joint venture with ICU Medical in the US
Otsuka Holdings: Otsuka Pharmaceutical Factory, Inc. and ICU Medical Announce the Establishment of Joint Venture
Otsuka Holdings: Treasury stock purchase status report (based on Act Section 24-6 (1))
Otsuka Holdings: Extraordinary Report
Otsuka Holdings: Corrected Issuance Registration Form
Otsuka Holdings: Notice regarding the status of share buybacks
Otsuka Holdings: Notice Regarding the Status of Share Repurchases
Otsuka Holdings: Notice regarding the change of representative director
Otsuka Holdings: Changes of Representative Director
Otsuka Holdings: Summary of financial results for the 3rd quarter of the fiscal year ending 2024/12 [IFRS] (consolidated)
Otsuka Holdings: Consolidated Financial Results for the Nine-Month Period Ended September 30, 2024 [IFRS]
Otsuka Holdings: Otsuka Announces Positive Interim Results from the Phase 3 Trial of Sibeprenlimab for the Treatment of Immunoglobulin A Nephropathy in Adults
Otsuka Holdings: Good interim analysis results of the phase 3 trial targeting the novel APRIL antibody “sibeprenlimab” IgA nephropathy
Otsuka Holdings: Treasury stock purchase status report (based on Act Section 24-6 (1))
Otsuka Holdings: Notice regarding the status of share buybacks